Risk factors for the development and progression of diabetic nephropathy by Hussin, Ahmad Munawwir
RISK FACTORS FOR THE DEVELOPMENT 
AND 
PROGRESSION OF DIABETIC NEPHROPATHY 
By 
DR AHMAD MUNA WWIR HUSSIN 
Dissertation Submitted In Partial Fulfillment 
Of The Requirements For 
THE DEGREE OF MASTER OF MEDICINE 
(INTERNAL MEDICINE) 
UNIVERSITY SAINS MALAYSIA 
2002 
I'-
ACKNOWLEDGEMENTS 
I would like to thank my supervisors, Associate professor (Dr) Zainal Dams 
and Associate professor (Dr) Rusli Ismail for their valuable advice and 
guidance on the preparation of this dissertation. 
Also to my beloved wife Dr Azma Azalina Ahmad Alwi for her 
understanding , ms Aisya for statistical assistance and not to forget to all my 
friends for their support 
ABSTRAK 
Factor-faktor risiko yang menyebabkan terjadinya nefropathi diabetes dan 
menyumbang kepada kemerosotannya. 
RINGKASAN 
Satu kajian telah dijalankan di Hospital Universiti Sains Malaysia dati tahmt 
1997 hingga 2000 untuk mengkaji factor-faktor risiko terhadap terjadinya 
nefropathi diabetes dan menyumbang kepada kemerosotannya di kalangan 
pesakit diabetes. 
OBJEKTIF KAJIAN 
1. Untuk mengenalpasti factor-faktor risiko yang menyebabkan 
terjadinya penyakit nefropathi diabetes 
2. Untuk mengenalpasti factor-faktor risiko yang menyumbang 
kepada kemerosotan nefropati diabetes. 
KAEDAH PENYELIDIKAN 
Kajian ini dijalankan secara "retrospective" di mana rekod pesakit-pesakit 
diabetes mellitus jenis 2 yang secara klinikalnya mengalami nefropati atau 
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tidak. Pesakit-pesakit ini dibahagikan kepada dua kumpulan iaitu 
normoalbuminmia dan makroalbuminuria berdasarkan kepada tahap 
kandungan protein dalam urin 24 jam dan juga dalam ujian dipstick urin 
protein. Data-data yang berkaitan juga diambil dari rekod pesakit. 
KEPUTUSAN 
Sebanyak: 200 rekod pesakit telah dikaji, di mana hanya 86 rekod sahaja 
yang telah dimasukkan dalam analisis akhir. Daripada jumlah ini, sebanyak 
25 pesakit termasuk dalam kumpulan normoalbuminuria dan 61 dalam 
kumpulan makroalbuminwia. Didapati bahawa hanya darah tinggi sahaja 
yang merupakan satu-satunya variabel yang mempunyai perbezaan yang 
signiftkan di antara kedua-dua kumpulan tersebut (p=0.03). Apabila ujian 
multivariate menggunakan 'logistic regression' dilakukan, didapati bahawa 
jangkamasa diabetes, paras trigliserid dan tabiat merokok memberikan 
sumbangan yang signiftkan kepada risiko terjadinya nefropathi diabetes. 
Pesakit yang mengalami kemerosotan fungsi buah pinggang yang cepat 
didapati mempunyai min tekanan darah arteri (p=0.02), tekanan darah 
sistolik (p=0.03), tekanan darah diastolik (p=0.04) dan juga kandungan 
111 
kumuhan protin dalam urin (p=O.Ol) yang lebih tinggi dan signifikan bila 
dibandingkan dengan pesakit yang mengalami kemerosotan yang lambat. 
Kesimpulan 
Faktor-faktor risiko yang di dapati menyebabkan terjadinya nefropati 
diabetes adalahjangkamasa diabetes, paras trigliserid dan tabiat merokok 
manakala yang menyumbang kepada kemerosotannya adalah darah tinggi, 
kandungan protin dalam urin yang dikumpulkan dalam 24 jam dan 
kehadiran riwayat diabetes dalam keluarga. 
Kata kunci 
Diabetes mellitus jenis 2, nefropati, faktor-faktor risiko 
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ABSTRACT 
Risk factors for the development and progression of diabetic nephropathy 
Introduction 
A study had been carried out in Hospital University Sains Malaysia from 
1997 to 2000 to investigate on development and progression of diabetic 
nephropathy. 
Objective 
1. To identify risk factors for the development of diabetic nephropathy 
2. To identify risk factors for the progression of diabetic nephropathy 
Methodology 
This is a retrospective study. Case records belonging to patients with type 2 
diabetes with and without nephropathy were reviewed. They were then 
v 
grouped into either normoalbuminuria and macroalbuminuria based on their 
24 hour urine protein and urine dipstick test for protein. Other related data 
was also extracted. 
Result 
Of the 200 case notes reviewed, only 86 were included in the final analyses. 
Twenty five of whom had normoalbuminuria and 61 had macroalbuminuria. 
On univariate analysis, it was noted that hypertension was the only variable 
showing significant difference between the two groups (P = 0.03). On 
mutivariate analysis using logistic regression it was noted that the duration 
of diabetes mellitus, the levels of serum triglycerides and smoking 
significantly contributed to the development of diabetic nephropathy. 
When compared between patients with rapid and slow progression of renal 
disease, patients with rapid progression had significantly higher mean 
arterial pressure (P=0.02), systolic blood pressure (P=0.03), diastolic blood 
pressure (P= 0.04) and has greater protein excretion. In addition the patient 
with rapid progression had significant strong family history of diabetes 
mellitus (P = 0.05). 
V1 
Conclusion 
Risk factors for the development of diabetic nephropathy were duration of 
diabetes, serum triglycerides, and smoking habit while risk factors for the 
progression of diabetic nephropathy were hypertension, 24 hour urine 
protein and family history of diabetes. 
Keywords 
Type 2 diabetes mellitus, nephropathy, risk factors 
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REFERENCES 
INTRODUCTION 
Diabetic nephropathy is a devastating complication of diabetes. Why some 
diabetic persons are susceptible to diabetic nephropathy and others are not 
has intrigued investigators. Many believe that hypertension (Hostetter 1982; 
Schmitz et al. 1994; Parving et al. 1983) and poor glycaemic control lead to 
nephropathy (RG Larkin 1996). It is likely that the pathophysiology of 
diabetic nephropathy involves an interaction of metabolic and 
haemodynamic factors (Cooper at al. 1996). Diabetic nephropathy has 
become the leading cause (25% to 42% of patients) of end stage renal 
disease (ESRD) in Europe (fig 1.1 ), Japan, and the United States.A Similar 
pattern was seen in Singapore where diabetic nephropathy accounted for 
31% of ESRD (Woo 1997). This problem will continue to rise as the 
incidence of diabetes mellitus throughout the world is expected to double 
within the next 10 years (fig 1.2). 
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Figure 1.1: Bar chart showing incidence ofESRD due to diabetes in 
Europe from 1970-90 
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Figure 1.2: Projected rise of diabetes in the world population by 2010 
1.1 Epidemiology of diabetic nephropathy 
Diabetic nephropathy can occur in both type 1 and type 2 diabetes mellitus, 
and the risk of nephropathy with progression to end stage renal disease is 
similar in both groups (Ritz et al. 1999). In a study by Pugh (1993), 
hyperglycaemia was found to be the most dominant contributing factor for 
the progression towards ESRD in type 1 diabetes whereas hypertension 
played a more dominant role in type 2 diabetes. However, the late phase of 
progressive renal disease towards ESRD in both groups showed similar 
profile. The epidemiology of diabetic nephropathy in type I diabetes had 
been well studied as compared to type 2 diabetes. This is because the onset 
of type I diabetes is obvious and its natural history can be closely followed 
thereof In contrast, the date of onset in type 2 diabetes is often unknown 
and the low grade albuminuria is less specific as an indicator of renal disease 
progression (Ismail et al. 1999). 
The peak onset of nephropathy in Type 1 diabetes is between 1 0 to 15 years 
after its onset. For those patients who did not have proteinuria after 20 to 25 
years of diabetes, the risk of progressing to overt renal failure was only 
about one percent per year (Cowie et al. 1989). On the other hand, the Pima 
Indian has provided useful information on type 2 diabetes. This native 
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American tribe has the highest prevalence of diabetes in the world where 
70% of adults suffer from type 2 diabetes. In this well studied population, 
the incidence of ESRD attributed to diabetic nephropathy increased from 0 
cases/1000 person-years at 0-5 years to 40.8 cases/1000 person-years when 
the duration of diabetes was more than 20 years (Nelson 1996, 1998). 
1.2 Natural history of diabetic nephropathy 
Stages of Diabetic Nephropathy according to Mogensen et al (1983) are 
divided into various phases: 
1. Early hypertrophy and hyperfiltration 
2. Silent phase 
3. Incipient nephropathy 
4. Clinical diabetic nephropathy 
5. End stage renal disease 
The above phases are well described in patients with type 1 diabetes and to 
some extent in type 2 diabetic patients. Type 2 diabetic patients often suffer 
from co-existing illnesses such as hypertension and etc. that can also lead to 
nephropathy via other pathogenetic processes. In a related study, the 
proportion of type 2 diabetic patients diagnosed to have some primary renal 
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disease ranged from 23 to 54.3% (Humprey et al. 1989). Therefore the 
natural history of nephropathy in type 2 diabetic can be unpredictable. 
1.2.1 Early Hypertrophy and Hyperfiltration 
This phase is characterized by renal enlargement, intrarenal hypertension 
and high GFR and is seen early in the course of diabetes (Rudberg, 1992). 
These haemodynamic phenomena are linked with the development of 
microalbuminuria and are partly reversible by good glycaemic and blood 
pressure control (Hostetter et al . 1982; Rudberg , 1992 ). 
1.2.2 Silent Phase 
Dwing this so-called silent phase early histological abnormalities in the 
kidney may be seen, including glomerular basement membrane hypertrophy 
and subtle thickening of glomerular basement membrane which are best seen 
under electron microscopy (Mogensen 1982). 
1.2.3 Incipient Nephropathy 
The earliest clinical evidence of nephropathy is the appearance of albumin in 
unne {>30 but <300mglday or <20Jlg/min), referred to as 
microalbuminuria.(See Table 3) Diabetic patients with microalbuminwia 
suffer from incipient nephropathy. A 24-hour urine protein collection is the 
gold standard for the detection of microalbuminuria (Bojestig et al. 1994). 
Fever, exercise, heart failure and poor glycaemic control are among the 
factors that can cause transient microalbuminuria (Mogensen et al. 1981). 
Microalbuminuria is associated with raised GFR. A normal GFR will in this 
context indicate loss of renal function (Damsgaard, 1993). The presence of 
persistent microalbuminuria is highly significant since it predicts the 
development of overt renal disease in both type 1 and type 2 diabetes 
(Viberti, 1982). Furthennore, microalbuminuria is associated with increased 
risk of cardiovascular and microvascular diabetic complications as well as 
increased mortality (Dinnen, 1997; Mogensen, 1981 ), especially in type 2 
diabetes. Renal histology at this stage reveals typical glomerulosclerosis. 
1.2.4 Clinical Diabetic Nephropathy 
Diabetic patients with urinary albumin excretion rates above 20J.1g/min or 
300mg/day qualify for overt diabetic nephropathy. This is usually associated 
with relentless loss of GFR by (1 to 24 mls/min/year) until ESRF 
supervenes. 
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Proteinuria is generally regarded as a marker for the degree of glomerular 
damage. The level of proteinuria correlates well with the prognosis for renal 
function. Any intervention that retards the progression of diabetic renal 
disease also reduces proteinuria (Cooper, 1998) 
1.2.5 End Stage Renal Disease 
Diabetic patients who require renal replacement therapy to sustain renal 
function are considered to have ESRD. It is characterized by generalized 
glomerular death and very low GFR. They usually have GFR of less than 
lOmls/min. 
Table 3. Table showing quantity of urine albumin for different categories of 
albuminuria in diabetic nephropathy. 
Category 24-Hr Timed Spot collection 
collection collection (p.glmg 
(mg/24h) (JJ.g/min )_ creatinine) 
Nonnal <30 <20 <30 
Microalbuminuria 30-300 20-200 30-300 
Clinical albuminuria >300 >200 >300 
( From Amencan Diabetes Association: Practice Recommendation 2000 ) 
1.3 Risk Factors for development and progression of Diabetes 
Nephropathy 
Diabetes nephropathy is a common problem, most likely to occur in patients 
who have poor glycaemic control, hypertension, glomerular hyperfiltration, 
or who are black, Mexican or Pima Indian (Burton, 2001). 
1.3.1 Hypertension 
Hypertension is much more common amongst diabetic patient than in 
general population and has been indentified as a major risk factor for both 
macrovascular and microvascular complications including diabetic 
nephropathy. Systemic hypertension has adverse effect on the kidney and 
may initiate the development of renal disease (as in hypertensive 
nephrosclerosis) or accelerate loss of function in the kidney in which 
parenchymal disease has already established. The mechanism by which 
hypertension damages the kidney in renal disease is not clearly understood. 
It may produce vascular hypertrophy which in turn leads to ischaemic 
glomerulosclerosis. On the other hand systemic hypertension may induce 
glomerulosclerosis by producing intraglomerular hypertension, which 
increases glomerular blood flow and filtration rate per nephron, leading to 
endothelial-cell damage (Klahr et al. 1998). Many patients with type 2 
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diabetes are hypertensive from the onset of diabetes as opposed to type I 
diabetes, in whom hypertension develop later (Simonson, 1988). 
1.3.2 Glycaemic control 
Type 1 and type 2 diabetes both have in common the state of chronic 
hyperglycaemia, and glucose dependent processes are likely involved in the 
pathogenesis of diabetic complications, including nephropathy. Glucose-
induced tissue injury may be mediated by the generation of advanced 
glycated proteins or via other mechanism such as poly-ol pathway, both of 
which have been implicated in nephropathy (Larkin et al. 1992). 
1.3.3 Hyperlipidaemia 
Hyperlipidaemia is common in both type 1 and type 2 diabetes. Raised 
plasma TG and low level of HDL has been correlated with the development 
of diabetic nephropathy as well as with cardiovascular complication (Gilbert 
et al. 1993; Nyberg et al.1987). Several studies in patient with type 1 and 
type 2 diabetes have shown correlation between serum cholesterol 
concentration and progression of diabetic nephropathy (Breyer 1996, Gall 
1993, Stefanski 1996). Moorheaed JF (1982), hypothesized that chronic 
progressive kidney disease may be mediated by abnormal lipid metabolism. 
A series of self-perpetuating secondary events follow an initial glomerular 
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mJury. Increased glomerular basement membrane permeability leads to loss 
of lipoprotein lipase activators, resulting in hyperlipidaemia. The close 
resemblance of mesangial cells to smooth muscle cells and the key role of 
the latter in the pathogenesis lead to atherosclerosis. Lipoprotein which 
function as a carrier for lipid, has surface receptors in many cells, including 
smooth muscle cells and probably mesangial cells. (Saulo Klahr, 1988). 
1.3.4 Genetic Susceptibility and Race 
Genetic susceptibility may be an important determinant of both the 
incidence and severity of diabetic nephropathy (Cooper et al. 1998; 
K.rolewski 1999). Krolewski (1999) also showed that the likelihood of 
developing diabetic nephropathy was markedly increased in patients with 
diabetic siblings or parents who also had diabetic nephropathy. This 
observation had been made in both type 1 and type 2 diabetes. (Krolewski, 
1999). People are looking at the influence of genes as a cause of diabetic 
nephropathy. It is unlikely to expect only a single gene to be involved. 
Multiple genes may contribute because diabetes mellitus is considered as a 
complex multifactorial disease (Remuzzi et al. 1998). 
Can we therefore invoke genetic susceptibility in diabetic nephropathy? 
Quinn ( 1996) reported that diabetic siblings of a person with type 1 diabetes 
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and nephropathy has a 72% cumulative risk of developing renal disease, 
while a diabetic sibling of a person with type 1 diabetes but without 
nephropathy only has 25% risk. 
One report for example, evaluated a Pima Indian family with 2 generations 
who had type 2 diabetes. The likelihood of their offspring developing overt 
proteinuria was 14%, 23% and 46% if neither parents had proteinuria, one 
parent with proteinuria, and both parents had proteinuria respectively 
(Pettitt, 1990). Therefore genetic factors are likely to be important in 
diabetic nephropathy. Recent interest has focused on genes of the Renin 
Angiotensin System, which are known to be polymorphic and have been 
extensively studied in relation to cardiovascular disease. Deletion-deletion 
(DD polymorphism) has been associated with an increased risk for the 
development of diabetic nephropathy, more severe proteinuria and a greater 
likelihood of progressive renal failure (Jeffers, 1997). 
Other factors that have been implicated in the development of diabetic 
nephropathy included; Transforming Growth Factor Beta (TGFP) gene 
(Sharma et al. 1997) and advanced glycation end (AGE) product (Makita, 
1991). 
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The incidence and severity ofDN were found increased in black (3 to 6 fold 
compared to Caucasians), Mexican-Americans and Pima Indian with type 2 
diabetes mellitus. 
1.3.5 Smoking 
Smoking is an important predictor of risk for renal complication in type 1 
diabetes (Sawicki, 1994). Olivarus et al. (1993) examined male patients 
with newly diagnosed type 2 diabetes and found that heavy albuminuria was 
more common in smokers (8.2%) and former smokers (7.3%) than in non 
smokers (2.1 %). 
Tobacco smoking can cause vasoconstriction, impaired platelet function, and 
abnormal regulation of coagulation and blood pressure (Patterson, 1998). 
Smoking was associated with an increase in serum creatinine (Bleyer, 2000). 
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1.4 Treatment 
Trea1ment for diabetic nephropathy can be divided into: 
a. Primary prevention: Treatment applied to normoalbuminuria 
patient 
b. Secondary prevention: Treatment applied to diabetic patients at 
high risk (microalbuminuria) 
c. Tertiary prevention: Treatment of overt nephropathy aimed 
at preventing or delaying development 
ofESRD 
1.4.1 Primary prevention 
Several studies showed that glycaemic control will delay progression to 
nephropathy in normoalbuminuria (yvang 1993, DCCT trial 1993). Three 
RCTs documented a benefit in blood pressure control which retards the 
development of diabetic nephropathy, in type 1 and type 2 diabetes (Euclid 
study group 1997; Ravid, 1998; Hope study 2000). 
1.4.2 Secondary prevention 
A meta-analysis of 12 trials m 698 type 1 diabetic patients with 
microalbuminuria who were followed up for at least one year revealed that 
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ACE-inhibition reduced the risk of progression to macroalbuminuria by 62% 
compared to that of the placebo group [odds ratio 0.38 (95% CI, 0.25 to 
0.57)] (The ACE inhibitor in Diabetic Nephropathy Trialist Group. 2001). 
The result in type 2 Diabetes also showed similar beneficial effect when 
followed up for 15 years (UKPDS 1998 ;StenoType 2 .1999). It was also 
shown that good blood pressure control slows down renal function 
deterioration regardless of the type of antihypertensive used (UKPDS 1998). 
1.4.3 Tertiary prevention 
Blood pressure lowering in Type 1 Diabetes with nephropathy for long term 
anti-hypertensive (Mogensen 1982). There is evidence for a beneficial 
effect of ACE-I above and beyond blood pressure control (Bjorck et al. 1992 
;Lewis et al. 1993) 
1.5 RECENT TRIALS using Angiotensin receptor blockade 
1.5.1 IRMA ll (Irbesartan Microalbuminuria Type 2 Diabetes m 
Hypertension Patient) 
Irbesartan was shown to significantly slow the development ofDN. It 
was also shown to have renoprotective properties independent of its 
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blood pressure-lowering effect in patient with type 2 diabetes and 
microalbwninuria. At 2 years, the adjusted risk of developing 
nephropathy was reduced by 68 % and the albumin excretion rate 
improved by 46 % in the high dose Irbesartan group (300mg/d) 
compared with placebo. (Parving et al. 2001). 
1.5.2 IDNT (Irbesartan Diabetic Nephropathy Trial) 
In another study also using Irbesartan it was shown to be effective in 
protecting against the progression of nephropathy due to type 2 
diabetes. (Lewis EJ et al. 2001) 
1.5.2 RENAAL (Reduction of End points in Non insulin dependant with 
Angiotensin II Antagonist Losartan) 
This was a study of patients on Type 2 Diabetes with protenuria and 
elevated serum creatinine. They were randomized either to Losartan 
or Placebo and continued to receive conventional antihypertensive to 
achieved blood pressure control. The use of Losartan showed a 16 % 
relative risk reduction in doubling of serum creatinine level. It also 
showed reduced risk in the development of ESRD or death. 
(p = 0.024){Brenner et al. 2001) 
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To conclude, It is likely that potential interplay between metabolic and 
haemodynamic factors involved in the pathogenesis of DN. This is best 
illustrated in the following diagram (Cooper 1996). 
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Figure 1.3: Schematic representation of the biochemical and 
haemodynamic pathophysiology in the renal 
microcirculation of diabetic nephropathy. 
Legends: 
PKC:Protein kinase C 
TGF-8:Transforming growth factor- Beta 
VEGF:Vascular endothelial growth factors 
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OBJECTIVES 
2.1 Primary: 
I. To identify risk factors for the development of diabetic nephropathy 
2. To identify risk factors for progression of diabetic nephropathy 
2.2 Secondary: 
1. To know the prevalence of hypertension in type 2 diabetes mellitus 
patients 
2. To know the prevalence of retinopathy in type 2 diabetes mellitus 
3. To know the type of antihypertensive prescribed to the study 
population 
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METHODOLOGY 
3.1 Research design and methodology 
This study is a retrospective study conducted at Hospital University Science 
Malaysia from 1997 to 2001. 
3.2 Subjects 
Two hundreds case records were selected from the Endocrine Clinic as well 
as from the medical wards in Hospital University Sains Malaysia for review. 
A total of 86 patients who fulfilled the study inclusion criteria and who did 
not have exclusion criteria were further analysed. 
3.3 Inclusion criteria 
1. Type 2 Diabetes Mellitus 
2. Case records with documented 3 serum creatinine or more done 
within the last 3 years and the interval between the frrst and the third 
serum creatinine should be at least 2 years apart. 
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3.4 Exclusion criteria 
1. DM-Type 1 
2. End stage renal failure requiring dialysis 
3. Positive microalbuminwia (dip stick test) 
4. Presence of renal diseases other than diabetic nephropathy i.e urinary 
tract infection, renal calculi, glomerulonephritis. 
5. Overt heart failure 
6. Hemoglobinopathy 
The following data was extracted from his/her case records. 
1. Age and Gender 
2. Smoking habits 
3. Family history of diabetes 
4. Duration of diabetes 
5. Weight (kg) 
6. Height (m) 
7. Blood pressure 
8. Serum creatinine at least 3 times at various interval 
9. Level ofHbAlc 
10. Total cholesterol and triglyseride 
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11. Dipstick wine albumin 
12. 24 hour wine protein over the last 6 months. 
13. History of retinopathy 
14. History of hypertension 
15. Medication (Oral hypoglycemic and antihypertensive) 
Creatinine clearance was calculated using Cockcroft formula for adult 
(Klahr 1991) 
1. Adult male: 
CrCl = ((140-Age) x (weight) x 88.33 [conversion factor to mgldl]) 
72 x Serum Creatinine (mmol/L) 
2. Adult female: 
CrCl = 0.85 x ((140-Age) x (weight) x 88.33) 
72 x Serum Creatinine (mmol!L) 
3.5 Measurements Method. 
1. Plasma glucose: This was measured by glucose-oxidase method using 
a Beckman glucose analyzer. 
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2. Triglyceride, Total Cholesterol: The assays were done by enzymatic 
method using reagent from BIO Merieux ( France ) by Hitachi 705 
chemistry analyzer (Japan) 
3. Serum Creatinine: The assays were done by calometric method 
using reagents from Boehringer Mannheim ( Germany ) by Hitachi 
705 chemistry analyzer (Japan) 
3.6 Definition 
3.6.1 Diabetic Nephropathy 
Defmed as a clinical syndrome that is characterized by persistent 
protenuria (microalbuminuria or macroalbuminuria), blood pressure 
elevation, with or without renal impairment, in the absence of other 
primary kidney disease. (Parving 2001) 
3.6.2 Type 2 Diabetes Mellitus 
The following criterias were used for the diagnosis of diabetes. 
• Random plasma glucose > 11.1 mmol/1 on 2 separate occasions 
with symptoms i.e. polyuria, polydipsia and unexplained weight 
loss or 
• Fasting plasma glucose> 7.0 mrnolll on 2 separate occasions or 
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• 2-hour plasma glucose > 11.1 mmol/1 during oral glucose 
tolerance test (OGTT) on 2 separate occasions 
(Expert committee on the Diagnosis and Classification of Diabetes 
Mellitus. 1997) 
3.6.3 Arterial Hypertension 
Was defmed as systolic blood pressure > 140mmHg or diastolic blood 
pressure > 90mmHg, or both, or patient was on antihypertensive. 
(Joint National Committee. 1997) 
3.6.4 Smoking Habit 
Current smokers: Subjects smoke one or more cigarette, 
cigar or pipe. 
Ex smokers: Defmed as subjects who reported having 
stopped smoking 
Non smoker: Patients who never smoked 
3.6.5 Hypercholesterolemia 
Total Cholesterol of more than or equal to 5.2 mmol!L. 
(Second Consensus Statement on Management of Hyperlipidaemia, 
MOH. 1998) 
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